Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis.

Y Dong; M D Walsh; M A McGuckin; B G Gabrielli; M C Cummings; R G Wright; T Hurst; S K Khoo; P G Parsons

doi:10.1002/(sici)1097-0215(19970220)74:1<57::aid-ijc10>3.0.co;2-f

Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis.

Identifier:nobleid.org/w1/20260515/2FC83644

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/2FC83644.svg?ark=w1%2F20260515%2F2FC83644)](https://nobleid.org/work/w1/20260515/2FC83644)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis.

Identifier:nobleid.org/w1/20260515/2FC83644

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/2FC83644.svg?ark=w1%2F20260515%2F2FC83644)](https://nobleid.org/work/w1/20260515/2FC83644)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work